An­a­lysts picked the top 4 block­buster con­tenders in the mix — and #1 is a $3.8B coin toss

Every year, the an­a­lysts at Clar­i­vate sort through the num­bers to see how many have a le­git­i­mate shot at break­ing in­to the cham­pi­onship ring of $1 bil­lion-plus block­busters.

Now, for the 8th straight year, they have a short list for which drugs bid­ding for — or re­cent­ly achiev­ing — an FDA ap­proval. And some of the picks may sur­prise you.

At the top, way out in front on peak po­ten­tial sales with a po­ten­tial $3.8 bil­lion an­nu­al bo­nan­za, sits ad­u­canum­ab, per­haps the most con­tro­ver­sial ther­a­py that’s made it through an ex­pert pan­el re­view — af­ter Sarep­ta’s eteplirsen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER